Steven Silver
Stock Analyst at Argus Research
(3.74)
# 1,977
Out of 4,455 analysts
23
Total ratings
80%
Success rate
21.1%
Average return
Main Sectors:
Stocks Rated by Steven Silver
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SPCX Space Exploration Technologies | Initiated Coverage: Hold | n/a | $153.23 | - | 1 | Jun 25, 2026 | |
| CVS CVS Health | Maintained: Buy | $90 → $104 | $104.34 | -0.33% | 4 | May 13, 2026 | |
| BAX Baxter International | Maintained: Hold | n/a | $22.04 | - | 4 | May 8, 2026 | |
| CAH Cardinal Health | Maintained: Buy | $189 → $248 | $237.92 | +4.24% | 4 | May 5, 2026 | |
| DXCM DexCom | Maintained: Buy | $100 → $90 | $70.14 | +28.31% | 2 | Nov 7, 2025 | |
| ITGR Integer Holdings | Downgraded: Hold | n/a | $93.89 | - | 2 | Oct 24, 2025 | |
| TZOO Travelzoo | Reiterated: Buy | $19 | $11.16 | n/a | 1 | May 11, 2022 | |
| THC Tenet Healthcare | Downgraded: Hold | n/a | $189.00 | n/a | 1 | Jun 13, 2014 | |
| ALNY Alnylam Pharmaceuticals | Rated: Buy | n/a | $291.37 | n/a | 2 | Jan 27, 2014 | |
| GILD Gilead Sciences | Maintained: Buy | $94 | $127.88 | n/a | 1 | Dec 9, 2013 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $15.71 | n/a | 1 | Oct 22, 2010 |
Space Exploration Technologies
Jun 25, 2026
Initiated Coverage: Hold
Price Target: n/a
Current: $153.23
Upside: -
CVS Health
May 13, 2026
Maintained: Buy
Price Target: $90 → $104
Current: $104.34
Upside: -0.33%
Baxter International
May 8, 2026
Maintained: Hold
Price Target: n/a
Current: $22.04
Upside: -
Cardinal Health
May 5, 2026
Maintained: Buy
Price Target: $189 → $248
Current: $237.92
Upside: +4.24%
DexCom
Nov 7, 2025
Maintained: Buy
Price Target: $100 → $90
Current: $70.14
Upside: +28.31%
Integer Holdings
Oct 24, 2025
Downgraded: Hold
Price Target: n/a
Current: $93.89
Upside: -
Travelzoo
May 11, 2022
Reiterated: Buy
Price Target: $19
Current: $11.16
Upside: n/a
Tenet Healthcare
Jun 13, 2014
Downgraded: Hold
Price Target: n/a
Current: $189.00
Upside: n/a
Alnylam Pharmaceuticals
Jan 27, 2014
Rated: Buy
Price Target: n/a
Current: $291.37
Upside: n/a
Gilead Sciences
Dec 9, 2013
Maintained: Buy
Price Target: $94
Current: $127.88
Upside: n/a
Oct 22, 2010
Maintained: Buy
Price Target: n/a
Current: $15.71
Upside: n/a